deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03386929

Survival Prolongation by Rationale Innovative Genomics (SPRING)

A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the Combination

Sponsor: ARC Foundation for Cancer Research

Conditions Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage IIIB
Interventions Avelumab Axitinib Palbociclib
Updated 14 times since 2018 Last updated: Nov 29, 2023 Started: Nov 29, 2017 Primary completion: Dec 29, 2022 Completion: Dec 29, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to the absence of funding necessary for the performance of the Phase 2.

Other terminated trials from ARC Foundation for Cancer Research

More terminations from ARC Foundation for Cancer Research

A PHASE1/PHASE2 clinical study on Non-small Cell Lung Cancer Metastatic and Non-small Cell Lung Cancer Stage IIIB, this trial is terminated or withdrawn. The trial is conducted by ARC Foundation for Cancer Research and has accumulated 14 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2019 · 14 months · monthly snapshot~Oct 2019 – ~Jul 2020 · 9 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Oct 2023 · 8 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Nov 2023 — Jan 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Oct 2023 — Nov 2023 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Feb 2023 — Oct 2023 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  2. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Oct 2019 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2018 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ARC Foundation for Cancer Research
  • Pfizer
  • Worldwide Innovative Network Association
Data source: Worldwide Innovative Network Association

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations